Low rate of reinfection among a cohort of people who use drugs successfully treated for hepatitis C virus infection in Vancouver, Canada

Holeksa, Julie; Magel, Tianna; Alimohammadi, Arshia; Thiam, Abdoulaye; Yung, Rossitta; Chu, Letitia; Truong, David; Conway, Brian

doi:10.1016/j.drugpo.2019.05.024

Cited by 11 publications

(10 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Almost all HCV-infected PWID referred to our SerDs were promptly treated, showing a good compliance to therapy. The high rate of SVR reported in both clinical trials and reallife observations around the world [6,7,[19][20][21][22][23][24] was also confirmed in our study. Moreover, our results corroborate those reported in a similar experience that prospectively recruited about 1500 PWIDs inside SerDs distributed all over Italy [25].…”

Section: Discussionsupporting

confidence: 88%

Model of Care for Microelimination of Hepatitis C Virus Infection among People Who Inject Drugs

Foschi

Borghi

Grassi

et al. 2021

JCM

View full text Add to dashboard Cite

Background: People who inject drugs (PWID) are the largest group at risk for HCV infection. Despite the direct acting antivirals (DAA) advancements, HCV elimination has been hindered by real-life difficulties in PWID. Aims: This study aimed to assess the impact of a multidisciplinary intervention strategy where HCV screening, treatment and follow-up were performed at the same location on efficacy and safety of DAA-therapy in real-life PWID population. Methods: All HCV-infected PWID referred to five specialized outpatient centers for drug addicts (SerDs) in Northern Italy were prospectively enrolled from May 2015 to December 2019. Hepatologists and SerDs healthcare workers collaborated together in the management of PWID inside the SerDs. Sustained virologic response (SVR), safety of treatment, proportion of patients lost to follow-up and reinfection rate were evaluated. Results: A total of 358 PWID started antiviral treatment. About 50% of patients had advanced fibrosis/cirrhosis, 69% received opioid substitution treatment, and 20.7% self-reported recent injecting use. SVR was achieved in 338 (94.4%) patients. Two patients died during treatment; one prematurely discontinued, resulting in a non-responder; twelve were lost during treatment/follow-up; and five relapsed. No serious adverse events were reported. SVR was lower in recent PWID than in former ones (89.2% vs. 95.8%; p = 0.028). Seven reinfections were detected, equating to an incidence of 1.25/100 person-years. Reinfection was associated with recent drug use (OR 11.07, 95%CI 2.10–58.38; p = 0.005). Conclusion: Our embedded treatment model could be appropriate to increase the linkage to care of HCV-infected PWID. In this setting, DAA regimens are well tolerated and highly effective, achieving a lower rate of reinfection.

show abstract

Section: Discussionsupporting

confidence: 88%

Model of Care for Microelimination of Hepatitis C Virus Infection among People Who Inject Drugs

Foschi

Borghi

Grassi

et al. 2021

JCM

View full text Add to dashboard Cite

show abstract

“…In BC, many care providers who provide HCV treatment to PWID incorporate a more comprehensive model including social support and addiction care. 35,36 On the other hand, engagement in HCV care and treatment could also be related to overall life stability and readiness for treatment, which may be contributing to decreased drug-related mortality. 37 Further studies are needed to understand the role of specific behavioural, pharmacological and care related factors associated with reduce drug-related mortality.…”

Section: Discussionmentioning

confidence: 99%

Impact of direct-acting antivirals for HCV on mortality in a large population-based cohort study

Janjua

Wong

Abdia

et al. 2021

Journal of Hepatology

View full text Add to dashboard Cite

show abstract

“…Nineteen studies were identified assessing recurrence in high‐risk patients who achieved SVR following DAAs therapy 14,15,21,27‐29,45‐57 . The median follow‐up time post‐SVR was 17 months (interquartile range, 9‐21).…”

Section: Resultsmentioning

confidence: 99%

“…Nineteen studies were identified assessing recurrence in high-risk patients who achieved SVR following DAAs therapy. 14,15,21,[27][28][29][45][46][47][48][49][50][51][52][53][54][55][56][57] The median follow-up time post-SVR was 17 months (interquartile range, 9-21). Of those studies, four evaluated the risk in prisoners, 15,49,53,56 S2).…”

Section: High-risk Hcv-mono-infected Populationmentioning

confidence: 99%

The risk of hepatitis C virus recurrence in hepatitis C virus‐infected patients treated with direct‐acting antivirals after achieving a sustained virological response: A comprehensive analysis

Huang

Wang

Yue

et al. 2021

Liver International

View full text Add to dashboard Cite

Background & Aims The risk for hepatitis C virus (HCV) recurrence persists after HCV eradication with direct‐acting antivirals (DAAs), particularly in patients with ongoing high‐risk behaviours. Our aim was to assess the risk of HCV recurrence (late relapse and/or reinfection) post‐sustained virological response (SVR). Methods We searched the literature for studies reporting HCV recurrence rates post‐SVR in PubMed, Web of Science and the Cochrane Library. Identified publications were divided into groups based on patient risk for HCV reinfection: low‐risk HCV mono‐infection, high‐risk HCV mono‐infection and a human immunodeficiency virus (HIV)/HCV coinfection. The HCV recurrence rate for each study was calculated by using events divided by the person‐years of follow‐up (PYFU). HCV recurrence was defined as confirmed, detectable HCV RNA post‐SVR. Results In the 16 studies of low‐risk patients, the pooled recurrence rate was 0.89/1000 PYFU (95% confidence interval [CI], 0.16‐2.03). For the 19 studies of high‐risk patients, the pooled recurrence rate was 29.37/1000 PYFU (95% CI, 15.54‐46.91). For the eight studies of HIV/HCV‐coinfected patients, the pooled recurrence rate was 23.25/1000 PYFU (95% CI, 4.24‐53.39). The higher pooled estimates of recurrence in the high‐risk and HIV/HCV‐coinfected populations were predominantly driven by an increase in reinfection rather than late relapse. Conclusions The HCV recurrence risk after achieving SVR with all‐oral DAAs therapy is low, and the risk of HCV recurrence in high‐risk and HIV/HCV‐coinfected populations was driven by an increase in reinfection rather than late relapse.

show abstract

Low rate of reinfection among a cohort of people who use drugs successfully treated for hepatitis C virus infection in Vancouver, Canada

Cited by 11 publications

References 10 publications

Model of Care for Microelimination of Hepatitis C Virus Infection among People Who Inject Drugs

Model of Care for Microelimination of Hepatitis C Virus Infection among People Who Inject Drugs

Impact of direct-acting antivirals for HCV on mortality in a large population-based cohort study

The risk of hepatitis C virus recurrence in hepatitis C virus‐infected patients treated with direct‐acting antivirals after achieving a sustained virological response: A comprehensive analysis

Contact Info

Product

Resources

About